Equities analysts anticipate that Sucampo Pharmaceuticals, Inc. will post $1.22 EPS for the current fiscal year. Recently, investment analysts covering the stock have updated the mean rating to 1.8. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0.
Mizuho reissued their neutral rating on shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) in a research report report published on Wednesday, January 3rd, MarketBeat reports. The biopharmaceutical company reported $0.27 EPS for the quarter, topping the Zacks' consensus estimate of $0.25 by $0.02. According to these analysts, the Low Revenue Estimate for Sucampo Pharmaceuticals, Inc.is 73 Million and the High Revenue Estimate is 77.7 Million. The company's net profit margin has achieved the current level of -60.2 percent and possesses 72.8 percent gross margin. Following the completion of the sale, the insider now directly owns 52,023 shares in the company, valued at approximately $858,379.50. The firm has "Buy" rating by Maxim Group given on Monday, June 12.
Sucampo Pharmaceuticals, Inc. (SCMP) analysts on average have given a price target of $25.15 on SCMP stock. Jefferies Group LLC reiterated a "hold" rating and issued a $16.00 target price (up previously from $14.00) on shares of Sucampo Pharmaceuticals in a report on Friday, November 11th. Instinet started coverage on shares of Sucampo Pharmaceuticals in a research report on Tuesday, December 19th. They set a buy rating and a $43.00 target price on the stock. Sucampo Pharmaceuticals presently has an average rating of Buy and an average price target of $21.58. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has a 20-Day average volume of 4.32 Million. The company had a trading volume of 1,988,800 shares, compared to its average volume of 4,260,200. The company has a market cap of $846.46, a P/E ratio of -5.49, a P/E/G ratio of 5.07 and a beta of 1.45. Sucampo Pharma has $43 highest and $11.0 lowest target. SCMP's financial leverage ratio is 8.79, which indicates that the company's asset base is primarily funded by debt.
Several hedge funds have recently bought and sold shares of the company. Arizona State Retirement System grew its position in Sucampo Pharmaceuticals by 1.6% during the second quarter. Last quarter, the company saw 61.27 million in total revenues. Rhumbline Advisers grew its position in Sucampo Pharmaceuticals by 0.9% during the second quarter. Thrivent Financial For Lutherans now owns 15,270 shares of the biopharmaceutical company's stock valued at $160,000 after purchasing an additional 1,550 shares during the last quarter.
It is interesting to note that Sucampo Pharmaceuticals, Inc. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company's stock valued at $126,000 after buying an additional 631 shares during the period. Royce & Associates LP now owns 1,171,731 shares of the biopharmaceutical company's stock worth $13,826,000 after buying an additional 103,808 shares during the last quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company's stock valued at $209,000 after purchasing an additional 790 shares during the last quarter. Vanguard Group Inc. increased its position in Sucampo Pharmaceuticals by 13.0% during the 2nd quarter.
As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Institutional investors own 65.29% of the company's stock.
In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the stock in a transaction that occurred on Thursday, December 7th. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. Leerink Swann also issued estimates for Sucampo Pharmaceuticals' FY2019 earnings at $1.79 EPS, FY2020 earnings at $2.02 EPS and FY2021 earnings at $2.19 EPS.
Analysts await Sucampo Pharmaceuticals, Inc. The Company's product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders.